Computer-based virtual reality assessments of functional capacity have shown promise as a reliable and valid way to assess individuals with multi-episode schizophrenia. However, there has been little research utilizing this innovative approach with young patients who are in the early phase of schizophrenia.
VeraSci’s proprietary Virtual Reality Functional Capacity Assessment Tool (VRFCAT) integrates virtual reality into the assessment of functioning in clinical trials. The VRFCAT is administered on a computer or our tablet-based platform, Pathway, and simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment. With demonstrated sensitivity to basic functional capacity deficits, the VRFCAT was developed to improve clinical trials by detecting functionally meaningful improvements in patients’ everyday lives. The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric and regulatory standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.
A recently published manuscript by Ventura et al., including as a co-author VeraSci’s CEO and Co-founder Dr. Richard Keefe, extended previous findings to patients with first-episode schizophrenia. Virtual-reality–based performance was correlated with a standard test of functional capacity, indicating VRFCAT validity. Furthermore, correlations with cognitive functioning and occupational/school and social functioning indicate promise as a coprimary measure to track changes in response to treatment.
CLICK HERE to read the full manuscript: Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning by
Joseph Ventura, Tamara Welikson, Arielle Ered, Kenneth L. Subotnik, Richard S. E. Keefe, Gerhard S. Hellemann, Keith H. Nuechterlein. Early Intervention in Psychiatry. 2019;1–9.